New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
08:41 EDTANIPANI Pharmaceuticals fundamentals appear on track, says Roth Capital
After ANI's stock came under considerable pressure, Roth Capital spoke with the company's management and thinks the company's fundamentals remain on track. The firm believes that the company's revenue and EPS could beat expectations, and it reiterates a Buy rating on the stock.
News For ANIP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
08:48 EDTANIPANI Pharmaceuticals price target raised to $78 from $65 at Roth Capital
Roth Capital hiked its price target on ANI as the firm expects the company's multiple to rise this year ,partially driven by a more diversified product mix and the company's increased cash that it can use to make accretive acquisitions. The firm keeps a Buy rating on the stock.
February 20, 2015
09:14 EDTANIPANI Pharmaceuticals 2015 guidance looks conservative, says Roth Capital
Subscribe for More Information
February 19, 2015
08:41 EDTANIPANI Pharmaceuticals sees FY15 adjusted EPS $2.48-$2.72, consensus $2.67
Subscribe for More Information
08:37 EDTANIPANI Pharmaceuticals reports Q4 adj EPS $1.94, may not compare to consensus 58c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use